NCT02337829 2026-01-08
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Acerta Pharma BV
Phase 2 Completed
Acerta Pharma BV
AstraZeneca
VA Office of Research and Development
University Hospital Southampton NHS Foundation Trust